711

AUTHOR INDEX

Abrahamsson, T., 82Adams, Jr., James D., 37Andrews, Allen F., 231Andrews, Allen F., 238

Argenbright, Lois S., 606

Arison, Byron A., 606Ashcroft, Susan B., 583Awazu, Shoji, 341

Azria, M., 699

Bai, S. A., 495

Baillie, Thomas A., 123

Balfour, Celia, 26

Barsotti, Deborah A., 1 17Bartels, M. J., 286

Bawarshi-Nassar, Rima N., 248Bayne, W. F., 166Belanger, Pierre M., 91

Benet, Leslie Z., 414Bergman, A., 441

Bergstrom, J., 709Berk, Paul D., 677

Bertilsson, Leif,433

Bickers, David R., 360

Birch, D. W., 106Birnbaum, Linda S., 506

Black, Ann, 662Black, Brigette, 677

Blair, Ian A., 625, 634

Blaschke, Terrence F., 49Bochner, Felix, 190

Boezeman, Jan B. M., 98Boudinot, F. Douglas, 590

Bowman, T. A., 160Brady, Pamela K., 231

Brady, Pamela K., 238

Brandt, I., 441Braselton, Jr., W. E., 406

Brouwer, Kenneth R., 646, 652Brundrett, Robert B., 402

Brunner, Lane J., 54

Buck, William B., 600Bugg#{233},Christopher J. L., 275Bugg#{233},Christopher J. L., 280Buhler, Donald R., 380

Buhler, Donald R., 387Bui, Hoang, 641Bulger, William H., 487Burckart, Gilbert J., 292Burka, Leo T., 612

Callery, Patrick S., 398Callery, Patrick S., 513

Cano, Jean Paul, 197Carpenter, Hillary M., 131Cassel, Mary E., 224Cederbaum, Arthur I., 694Chang, Tsun, 662Chen, I.-W., 166

Chen, 1-Wu, 426Chen, T. H., 406Chen, Tian-Ling, 402Chisima, Susumu, 455

Chu, Chung K., 590Clark, Mary Jo, 469

Clejan, Liviu A., 694

Coan, Mary, 420Coddington, Kathleen A., 600

Colby, H. D., 709Colby, Howard D., 186Cole, S. P. C., 551

Colvin, 0. Michael, 402

Combalbert, Jean, 197Conley, Barbara A., 398Cook, C. Edgar, 153Cook, Kathleen J., 518Coon,MinorJ.,7

Coon, William W., 271Corbin, Neal, 345

Cornfield, Linda J., 26Cox, Jeffrey, W., 373

Craig, John, 345

Cravanzola, Carlo, 437

Crooks, Peter A., 180Crooks, Peter A., 248

Cunningham, Michael L., 612Curtis, Lawrence R., 131

Dahl-Puustinen, Marja-Liisa, 433Dalet, Isabelle, 197Damani, L. A., 20Dannan, Ghazi A., 387

Dannecker, R., 699Darnerud, P. 0., 441Dean, Margaret, 87

Dean, Margaret E., 579

De Clercq, E., 683

deLuna, Florencia A., 147

Dent,J., 174Dent,JohnG., 117Derancourt, Jean, 197

de Vries, Michiel H., 573Dewey,R., 174Diliberto, Janet J., 506

Domino, Edward F., 271Dore, Francois M., 91Doshi, Kokila J., 590D’Souza, Martin J., 595

Duggan, D. E., 166Dumont, Etienne, 433Duncan,C.A., 166Du Souich, Patrick, 704Dvorchik, B. H., 160

Easterling, D. E., 495Eckardt, R., 174Eddy, A. Craig, 265Egger, H., 669

Egorin, Merrill J., 398Elo, Heikki A., 690

Fabre, Gerard, 197

Fabre, Isabelle, I 97Ferguson, Ronald J., 231Ferguson, Ronald J., 238Ferraiolo, B. L., 369

Fleckenstein, Lawrence, 304

Flowers, N. Lynn, 186

Forkert, P. G., 106Forkert,P.G., 551Franzone, Jos#{233}Sebastian, 437

Fujiyoka, Toshihiro, 77

Fukazawa, H., 463

Gabriel, Steve, 656

Gallo, James M., 590Gelboin, Harry V., 360Gelboin, H. V., 551

Gibaldi, Milo, 265

Godin, C. Steven, 180

Goldstein, Robin S., 139

Greenfield, John C., 518

Grillo, Mark P., 123Grosa, Giorgio, 437

Gruenke, Larry, 345Guengerich, F. Peter, 387

Haanen, Clemens, 98

Hachiyama, Shizuko, 77Halpert, James, 26

Halpin, R. A., 166Haney, C. A., 495Hartman, Neil R., 292Hassan, Aslam S., 600

Hatzinger, Paul B., 297Hayashi, Masahiro, 341Hayden, Patrick J., 297

Heimark, Larry D., 265

Hein,DavidW.,231Hem, David W., 238

Heintz, R., 463

Hicks, James L., 662Hill,JudithM., 153Hirayama, Hiroki, 556

Hoffman, Kurt-JUrgen, 69Hofman, Gerard A., 573

Hollenbach, S., 369Hook, Jerry B., 139Hooper, Wayne D., 212Hottlet, H#{233}l#{232}n,704Hovens, Christopher M., 190

Huang, Che C., 662

Huelle, Belinda K., 304Hughes, D. M., 160Huijzer, Jeannett C., 37

Hultgren, B., 369Hussain, Anwar A., 248

Iannucci, R., 669

Ichihara, S., 463lida, Satofumi, 341Ikeda, Yurika, 77Ikenishi, Yuji, 323Inaba,T., 330

Inaba, T., 334

Ishida, Takashi, 77Ito, Kenichi, 77

Iwakawa, Seigo, 414Iwase, Yukiko, 77

Iwatani, Kouji, 323

Jacob, III, Peyton, 224

Jacobs, Natalie L., 677

Jajoo, Hemant K., 625, 634Jardine, Ian, 292Jaw, John-Yan, 26Jaw, John-Yan, 37Jeffcoat, A. Robert, 153

Johansson, Benny, 351Johnson, P. B., 709Joly, R., 463Joyce, David A., 208

Jung, Donald, 365

Kadar, Dezso, 567

Kalow, W., 334Kalow, Werner, 567

Kassam, Jeanine P., 567

Kedderis, Gregory L., 606

Kedzierski, Bogdan, 380Kedzierski, Bogdan, 387

Kelly, Colleen, 393Keohane, D., 174

Kershaw, William C., 1 17Khan, Wasiuddin A., 360Kiang, Chin-Hen, 43Kirlin,WardG., 231

Kirlin, Ward G., 238Knapp, Joseph E., 292

Kochak, G., 669Kochhar, D. M., 618Koop, Dennis R., 694Koster, Andries Sj., 573

Kovacs, J., 330Krabil, Lavern, 393Krieter, Philip A., 14

Kubiak, Teresa, 393Kuhn, Christine, 360Kumagai, Yoshito, 77

Kupfer, David, 487Kushinsky, Stanley, 43

Kuslikis, B. I., 406

Labrecque, Gaston, 91

LaBudde, John A., 625, 634

Lacy, Steven A., 481La Delfa, Ignazio, 49Lage, Gary L., I 17

Lalande, Marcel, 91Lambert, Chantal, 704

Lamontagne, Daniel, 704Lan, S. J., 532

Larson,PhilipG., 373

Lee, Carol, 43Lee, Helen, 662

Lee, Ling-Jar, 32Lee, Shi-Fueng, 414

LeMaire, M., 699Leonard, Thomas B., 1 17Levitt, M., 709

Lignell, E., 82Lim, Weng Hua, 212

712 AUTHOR INDEX

Lin, Emil T., 414Lin, Fu-Tyan, 292Lin, Jiunn H., 147Lin, Jiunn H., 221

Lin, Jiunn H., 426Lindberg, Claes, 3 1 1Linssen, Peter C. M., 98Ludden, Thomas 0., 304

Luke, David R., 54

Mangold, Donald J., 304

Marbach, P., 699

Marlowe, Carolyn. 469Mash, Eugene A., 26

Massarella, Joseph W., 473Matthews, H. B., 612

Matthews, Hewitt W., 595Maurel, Patrick, 197Maurer, G., 699Mayol, Robert F., 625, 634

McCabe, J., 369

McHugh, Teresa A., 677McMahon, Timothy F., 506

McNamara, Patrick J., 646, 652Melder, D. C., 526Menargues, A., 673

Merk, Hans F., 360Mico,B., 174

Mico,BruceA., 139

Migdalof, B. H., 532Mihashi, Kunihide, 77

Mikulski, A., 82Miller, Michael A., 304Minutella, L. M., 618

Miura, Yuji, 455

Miwa, Gerald T., 606Mizojiri, Kenji, 564Mizuma, Takashi, 341Mo, Zhengji, 49

M#{246}nkk#{228}nen,Jukka,, 690

Morrison, Brent E., 583

Muirhead, Murray R., 190Mukhtar, Hasan, 360Murray, Michael, 449

Nakagawa, Kikuko, 64

Nakagawa, Yuzo, 323

Nakajima, Yoshikazu, 323Nakano, Masayuki, 323

Nakano, Masayuki, 564Nelson, Sidney D., 355

Newton,J.F., 174

Nieuwenhuijs, J., 1

Nishimura, Merry C., 224Niwa, Toshiro, 64

Noe, Dennis A., 402

Noguchi, Hideyo, 64

Nomen, M., 673Noordhoek, Jan, 573

Northroot, Helen, 345Nouws, J. F. M., 1

Obach, R., 673O’Donnell, John P., 186

Ogolla, Fredrick, 231Ogolla, Fredrick, 238

Okuda, Hirokai, 677O’Leary,IrvingA., 518

Olovson, 5-0., 82Osawa, Yoichi, 7Otterness, Diane, 255Owens, S. Michael, 641

Pang, Sandy K., 556

Park, Sang S., 360Park,S.S., 551

Parli, C. John, 656Parnonen, Petteri, 690Passananti, G. T., 160Peet, N. P., 495Penglis, Stan, 87

Penner,J.D.,6l8Perez-Reyes, Mario, 153Persson, Kerstin, 218

Petty, Brent G., 402

Pilon, Denis, 481Pitti, R., 369

Pitts, Lawrence H., 224

Plunkett, Laura M., 641Pohorecki, Roman, 271

Pollock, Stanley H., 595

Porubcan,M.A., 532Porubek, David J., 123Potter, Barry J., 677Potts, Brian D., 656

Powis,G., 526

Prasad, Pratapa P., 365

Pruett, J. K., 495Pru#{241}onosa,J., 673Pullen, Robert H., 373

Rane, Anders, 218Rashed, Mohamed S., 355

Rayburn, William, 271Reboani, Maria Camilla, 437

Reed, Ralph L., 380Reed, Ralph L., 387Reg#{226}rdh,C.-G., 82Reidy, Gordon F., 449

Renberg, Lars, 69Rettie, Allan E., 265

Reuning, Richard H., 583Rickert, Douglas E., 481

Rikans,LoraE., 114Roberts, Alan E., 481

Robertson, P., 669Rodriguez, Lolita C., 275

Rodriguez, Lolita C., 280Ronfeld, Robert A., 542

Ronfield, Robert A., 58Roos, Claes, 31 1

Ross, David, 348Rufino, F. A., 669

Sabramanyam, Babu, 398Sadler, Albert, 348Sadler, Brian M., 153

Sakuma, Noriko, 341

Sanchez-Barona, Dawn 0. T., 304Santos, George W., 402

Scanlan, L. M., 532Schwartz, M. S., 166Schweitzer, A., 699

Sherratt, A. J., 20

Sherry, J. H., 709Simmons, Roy, 420Simonsson, Roger, 69

Smith, David E., 32

Smith, F. A., 286

Smith, Jack L., 606Snyder, Stuart, 398Somogyi, Andrew A, 190

Sood, Virendra K., 373Spahn, Hildegard, 414

Speth, Paul A. J., 98Stancato, F., 669

Starzi, Thomas E., 292

Steams, Ralph A., 606Stevens, James L., 297

Stock, Beresford, 87Stock, Beresford H., 579Streeter, Anthony J., 355

Stroh, Justin G., 58

Stubbs,R.J., 166Suba, Eric, 348

Subrahmanyam, Vangala V., 348Suganuma, Toshiyuki, 414Sugeno, Koichi, 323

Sundaram, Rajah S., 255Svensson,LeifA.,31l

Swanson, Barbara R., 208

Swanson, Steven P., 600

Swynnerton, Nollie F., 304

Szinai, I., 683Szumlanski, Carol, 255

Takeyama, Shigeyuki, 455

Tang, Bing K., 567Tarloff, Joan B., 139Tateishi, M., 463Termond, Emiel F. S., 98

Thongnopnua, Phensri, 473Tocco, Dominick J., 147Toki, Satoshi, 77

Tokuma, Y., 64Tomisawa, H., 463

Tompkins, Gregory C., 54Trager, William F., 265Trapani, Angelo J., 14

Tremaine, Larry M., 58Tremaine, Larry M., 542

Trinidad, Alma, 231Trinidad, Alma, 238

Tunek, Anders, 31 1Turner, Jr., Max J., 481Tyndale, R. F., 334

Ulm,EdgarH., 147

Ulm, Edgar H., 426

Unger, S. E., 532

Urtti, Arto, 690

Vall#{234}s,J., 673Vane, Floie M., 275Vane, Floie M., 280

van Gogh, H., 1Van Loon, Jon A., 255

van Miert, A. S. J. P. A. M., 1Venkatarmanan, Raman, 292

Verburg, Michael T., 373Vesell, E. S., 160

Vessey,M.L.,55l

Vicchio, Domenick, 513Vickers, F. F., 160Vickers, S., 166

Vogelsang, Georgia B., 402

Wachtmeister, C. A., 441

Waddell, William J., 469

Wade, Denis N., 208Wahlstr#{246}m, Agneta, 218Walle, T., 495Walle, U. K., 495

Walsh, John S., 606Wang, C. Paul, 292

Warrack, B. M., 532Watson,A.D.J., 1

Wehler, E. Klasson, 441

Weinshilboum, Richard M., 255

Weinstein, S. H., 532Welch, Willard M., 542

Wessels, Hans M. C., 98Wiley, James N., 583Wilke, T. J., 526

Wilking, H., 369

Williams, David E., 380

Williams, David E., 387Wilson, M. J., 495Woolf, Thomas F., 662Wynalda, Michael A., 373

Xu, Xin, 556

Yamamoto, T., 469Yano, Masashi, 77Yarma, R. K., 532Yerokun, Tokunbo, 231Yerokun, Tokunbo, 238Ylitalo, Pauli, 690Yodis, L. P., 174Yost, Garold S., 37

Zhu, Quan Ming, 49Ziegler, Daniel M., 380Zimmerman, Cheryl L., 473Zorbas, Mark, 641

6-Acetamidohexanal, active aldehydic metabolite, hexamethylene bisa-

cetamide, 398Acetaminophen

N-hydroxylation of 3’-hydroxyacetanilide, 355nephrotoxicity, susceptibility, middle-aged rats, 139

transport of conjugates, hepatocytes (rats), 341N-Acetylisoniazid, isoniazid and, temporal variations, pharmacokinetics

(rats), 91

N-Acetyltransferasesbladder isozymes (hamsters), 231, 238isoniazid and N-acetylisoniazid, temporal variations, pharmacokinet-

ics (rats), 91Acitretin, pharmacokinetic disposition, influence of pregnancy (rats),

646, 652Acrylonitrile, metabolism to 2-cyanoethylene oxide, liver microsomes,

lung microsomes and lung cells (rats), 481Adrenal cortex, spironolactone metabolism (guinea pigs), 186

Adrenal gland, activation of spironolactone, regional differences (guineapigs), 709

Adriamycin, pharmacokinetics, hematopoietic cells (humans), 98

Aginghepatic drug metabolism (rats), 1 14middle-aged rats, susceptibility, acetaminophen nephrotoxicity, 139

-related changes in benzyl acetate disposition (rats), 506Albumin, conjugates, pharmacokinetics, D-penicillamine (rats), 208Alcohol dehydrogenase, liver variants, variety of substrates (humans),

567Aldehyde oxidase, activities ofdrug oxidases, cultured hepatocytes (rats),

20Allyl alcohol, hepatotoxicity, enhancement by methoxyflurane (rats),

117

Amiloride, renal tubular secretion, inhibition by cimetidine (humans,

rats),190

l-Aminobenzotriazole, inhibition of 3-methylindole bioactivation

(goats), 374-Amino-N-(2,6-dimethylphenyl)benzamide, metabolism and disposi-

tion, pharmacokinetics (rats), 656Amiodarone, -digoxin interaction, reduction, hepatic uptake (rats), 704

Anthracycline, hematopoietic cell pharmacokinetics (humans), 98

Antianxiety drugsbuspirone metabolism (humans), 634buspirone metabolism (rats), 625

Anticonvulsants, 4-amino-N-(2,6-dimethylphenyl)benzamide, metabo-lism and disposition (rats), 656

Antihypertensive agents, disposition of flavodilol (rats, rabbits), 420Anti-inflammatory agents, isoxicam, in vivo metabolism (rats, dogs,

monkeys), 662

Antimycotic agents, croconazole metabolism (rabbits), 323Antioxidants, U-74006F, pharmacokinetics, perfused liver (rats), 373

Antipyrinepotent inhibitor of metabolism, fluconazole (mice), 49test (dogs, monkeys), 160

Arthritis, adjuvant, pharmacokinetic analysis, cyclosporine (rats), 595Assays

antipynne test (dogs, monkeys), 160biotransformation of etretinate (mice), 618liquid chromatography mass spectrometry, bambuterol metabolism,

liver microsomes (rats), 31 1Atenolol, metoprolol and, central nervous system kinetics (dogs), 82

Atrial natriuretic peptide, metabolism of, extraction by organs (rats), 143’-Azido-3’-deoxythymidine, 3’-azido-2’,3’-dideoxyuridine and (mice),

Bambuterol, metabolism in liver microsomes (rats), 3 1 1

Benzyl acetate, age-related changes in disposition (rats), 506

humanidentification, etretinate metabolites. 275

isolation, cyclosporine metabolites, 292novel metabolite of morphine,

yl)dihydromorphinone (guinea pigs), 77Bile duct, enterohepatic circulation, T-2 toxin metabolites (rats), 600

Biphenyl, foreign compound-metabolizing activity, hepatocytes and liverslices (humans, dogs, rats), 526

4,4’-Bipyridyl, N-methylation as toxication route (guinea pigs), 180

Bladder, N-acetyltransferase isozymes (hamsters), 23 1 , 238fJ-Blockers, atenolol and metoprolol, central nervous system kinetics

(dogs), 82Blood, human, identification, etretinate metabolites, 275Bone marrow, stimulation of bioactivation of hydroquinone, phenol,

348

Bovine growth hormone-releasing factor analog, Leu27-gGRF(l-29)NH3,

metabolic degradation, bovine and porcine plasma, 393Brain, locomotor activity, doxofylline (rats), 437Bronchodilation, doxofylline, brain and locomotor activity (rats), 437

Buspironemetabolism (humans), 634metabolism (rats), 625

Carbamic acid ester glucuronide, characterization, sertraline carbamoyl-

O-glucuronide (dogs), 58

Carbonyl sulfide, copper chelating metabolite of disulfiram, 351

Carboxylic acid, metabolic conversion of2-propylpentanal, valproic acid,513

Carcinogensbladder N-acetyltransferase isozymes (hamsters), 23 1 , 238

2,6-diaminotoluene, metabolism and disposition (rats), 612Carprofen, diastereomeric glucuronides, direct determination (humans),

414

Central nervous system, kinetics, atenolol and metoprolol (dogs), 82

CGS 16617, physiological disposition (rats, dogs, humans), 669Chlordecone, pretreatment, characterization, altered pharmacokinetics

(mice), 131

5-(2-Chlorocthyl)-2’-deoxyuridine, biotransformation (mice), 683Chronopharmacokinetics, isoniazid and N-acetylisoniazid, temporal var-

iations (rats), 91Cilastatin

dose-dependent kinetics (rats, dogs), 426insulin interaction (rats), 54

Cimetidine, inhibition, renal tubular secretion of amiloride (humans,rats), 190

Clara cells, pulmonary toxicity of trichloroethylene (mice), 106Clodronate, uptake by macrophages (mice), 690

Clotrimazole, induction of hepatic cytochrome P.450, isozyme-specificmonoclonal antibody (rats), 360

Cocaine, disposition after intravenous injection, nasal insufflation, smok-ing (humans), 153

Copper, chelating metabolite ofdisulfiram, carbonyl sulfide, 351

Croconazoleantimycotic, deimidazolation, epoxide formation in liver microsomes

(rabbits), 564

metabolism (rabbits), 3232-Cyanoethylene oxide, metabolism of acrylonitrile, liver microsomes,

lung microsomes and lung cells (rats), 481

713

590

SUBJECT INDEX

Bile

(8S)-(glutathion-S-

714 SUBJECT INDEX

Cyclosporin A, metabolism (humans), 197Cyclosporine

isolation of metabolites, human bile, 292pharmacokinetic analysis, adjuvant arthritic rats, 595

Cysteine, conjugates, multiple metabolic pathways, 297Cytochrome P-450

activities of drug oxidases, cultured hepatocytes (rats), 20

anti-3a IgG inhibition of pyrazole oxidation, liver microsomes (rab-

bits), 694

deimidazolation of antimycotic croconazole, epoxide formation, livermicrosomes (rabbits), 564

flavin-containing monooxygenase, N-oxidation, senecionine (rats), 380

hepaticbioactivation and detoxication, senecionine (rats), 387induction by clotrimazole, isozyme-specific mAb (rats), 360

hepatic monooxygenase activity, influence of phenobarbital, gestation

stages (rats), 579immunohistochemical study, monoclonal antibodies, lung (mice), 551

inactivation of liver steroid hydroxylases (rats), 26

potent inhibitor ofantipyrine metabolism, fluconazole (mice), 49rifampicin-inducible, product, P45OIIIA gene subfamily (humans), 197

selective inactivation by phencyclidine (rabbits), 7stereoselective oxidation of nilvadipine (rats, dogs), 64suicide substrates, inhibition, 3-methylindole bioactivation (goats). 37

Cytochrome P-450 PB-B, formation of inhibitory complex, isosafrole

metabolite, liver microsomes (rats), 449

Cytosol, bladder N-acetyltransferase isozymes (hamsters), 231. 238

Darier’s disease, biotransformation of etretinate (mice), 618

Daunomycin, pharmacokinetics, hematopoietic cells (humans), 98Debrisoquine monooxygenase, sparteine, variant allozymes (humans),

334

6-Desmethylnaproxen sulfate, metabolite of naproxen, human plasma,43

Deuterium, -labeled metabolite of trimebutine, metabolic pathways

(rats), 455Diabetes, experimental, elimination kinetics, diflunisal (rats), 147

2,6-Diaminotoluene, metabolism and disposition (rats), 612Dichloromethylene bisphosphonate, uptake by macrophages (mice), 690Diet, influence of nutritional status, pharmacokinetics and pharmaco-

dynamics, pentobarbital (rats), 365Diflunisal

elimination kinetics, experimental diabetes (rats), I 47protein binding, species differences, 221

Digoxin, -amiodarone interaction, reduction, hepatic uptake (rats), 704Dihydropyridine, calcium antagonist nilvadipine, stereoselective oxida-

tion, liver (rats, dogs), 64N.N’-Dimethyl-4,4’-bipyridyl ion, N-methylation as toxication route

(guinea pigs), I 80

Dimethyl sulfoxide

inhibition of urethane metabolism (mice), 469intravenously administered, tissue distribution (rats), 224

Dipeptidylpeptidase, metabolic degradation of Leu27-gGRF(l-29)NH3,

bovine and porcine plasma, 393Disulfiram, copper chelating metabolite, carbonyl sulfide, 351Doxofylline, brain and locomotor activity (rats), 437

Ehrlichia phagoct’tophila, effect on sulfadimidine pharmacokinetics(goats), 1

Epoxide, formation in liver microsomes, deimidazolation, antimycoticcroconazole (rabbits), 564

17�3-Estradiol, progesterone and, nasal absorption and metabolism (rats),

248

Ethanol, liver alcohol dehydrogenase variants, variety of substrates (hu-mans), 567

Ethiofos, disposition (monkeys), 304

Etretinate

biotransformation (mice), 618identification of metabolites

human bile, 275

human blood, 280metabolites, pharmacokinetics (dogs), 473pharmacokinetic disposition, influence of pregnancy (rats), 646, 652

Flavin, -containing monooxygenase, N-oxidation, senecionine (rats), 380

Flavodilol, disposition (rats, rabbits), 420Fluconazole, potent inhibitor ofantipyrine metabolism (mice), 49

Furosemide, renal drug transport, effect, organ perfusion (rats), 32

Fusaria, T-2 toxin metabolites, enteroheptic circulation (rats), 600

Gestation, influence of phenobarbital, hepatic monooxygenase activity(rats), 579

Glucose, cilastatin-insulin interaction (rats), 54

Glucuronidation, metabolic interaction of morphine and naloxone, liver(humans), 218

Glucuronides, diastereomeric carprofen, direct determination (humans),

414

Glutathione-S-transferase, ligandin levels, dose-related effects, phenobar-bital (rats). 677

(85)-(Glutathion-S-yl)dihydromorphinone, novel metabolite of mor-phine from bile (guinea pigs), 77

Glycine, benzyle acetate disposition, aging-related changes (rats), 506

Haloperidol reductase, liver (humans, guinea pigs), 330Haloxyfop, stereochemical inversion (rats), 286

Hematopoietic cells, anthracycline pharmacokinetics (humans), 98Hepatocytes

activities of drug oxidases, cultured hepatocytes (rats), 20covalent binding to protein, valproic acid, hepatotoxic metabolite

(rats), 123decreased foreign compound-metabolizing activity, comparison to

liver slices (humans, dogs, rats), 526metabolism in subcellular fractions, nitrogen-containing steroid (rats),

606

reduction of uptake, amiodarone-digoxin interaction (rats), 704transport of acetaminophen conjugates (rats), 341

Hepatotoxicity. allyl alcohol, enhancement by methoxyflurane (rats),117

Hexamethylene bisacetamide, active aldehydic metabolite, 398Hydrogen peroxide, oxidation of tenoxicam, leukocyte peroxidases, 463Hydroquinone, stimulation of bioactivation by phenol, bone marrow

cells, 3482’-Hydroxy-3,4,4’-trichlorocarbanilide, sulfate conjugate, hydrolytic be-

havior, 345

3’-Hydroxyacetanilide, N-hydroxylation, 355L-a-Hydroxy acid oxidase, quantitation of multiple pathways of metab-

olism, nephrotoxic cysteine conjugates, 297Hydroxybiphenyl, foreign compound-metabolizing activity, hepatocytes

and liver slices (humans, dogs, rats), 52617a-Hydroxylase, adrenal activation of spironolactone, regional differ-

ences (guinea pigs), 709E-lO-Hydroxynortriptyline, glucuronidation in liver, kidney, intestine

(humans), 4335-Hydroxytryptamine, uptake blocker sertraline, metabolism and dis-

position, (rats, dogs), 542

Hypercholesterolemia, physiological disposition oflovastatin (dogs), 166

Idazoxan, oral bioavailability (rats), 673Imipenem, dose-dependent kinetics of cilastatin (rats, dogs), 426

Immunoglobulin G, anti-3a IgG inhibition of pyrazole oxidation, livermicrosomes (rabbits), 694

Insulin, cilastatin interaction (rats), 54

Intestineglucuronidation of E-lO-hydroxynortriptyline (humans), 433

SUBJECT INDEX 715

-liver preparation, first-pass metabolism, salicylamide (rats), 556

metabolism of atrial natriuretic peptide (rats), 14

oral idazoxan bioavailability (rats), 673

phenol sulfotransferase, assay conditions, thermolabile form, 255�

systemic metabolism of 1-naphthol (rats), 573Isoniazid, N-acetylisoniazid and, temporal variations, pharmacokinetics

(rats), 91Isosafrole, metabolite, formation of inhibitory complex, cytochrome P-

450 PB-B (rats), 449

Isoxicam, in vivo metabolism (rats, dogs, monkeys), 662

Kidneydose-dependent kinetics of cilastatin (rats, dogs), 426

drug transport, effect, organ perfusion (rats), 32glucuronidation of E-l0-hydroxynortriptyline (humans), 433metabolism of atrial natriuretic peptide (rats), 14nephrotoxic cysteine conjugates, quantitation, multiple metabolic

pathways, 297pharmacokinetics, recombinant tumor necrosis factor-a (rats), 369

renal tubular secretion ofamiloride, inhibition by cimetidine (humans,

rats),190

renin inhibitor peptide, U-7 1038 disposition and metabolism (rats),

518

spironolactone metabolism (guinea pigs), 186

Leu27-bGRF(l-29)NH3, metabolic degradation, bovine and porcineplasma, 393

Leukocytes, peroxidases, oxidation of tenoxicam, hydrogen peroxide,

463Ligandin, hepatic glutathione-S.transferase activity, dose-related effects,

phenobarbital (rats), 677

Lipids, hydroxylated metabolites of 3,3’,4,4’-tetrachlorobiphenyl, excre-tion and tissue retention (mice), 441

Liver

alcohol dehydrogenase variants, variety of substrates (humans), 567cytochrome P.450 enzymes, bioactivation and detoxication, senecion-

inc (rats), 387

cytochrome P-450 induction by clotrimazole, isozyme-specific mono-

clonal antibody (rats), 360

drug metabolism as function ofage (rats), 1 14factors affecting phencyclidine biotransformation (humans), 271glucuronidation of E-lO-hydroxynortriptyline (humans), 433

haloperidol reductase (humans, guinea pigs), 330hepatic first-pass effect, oral idazoxan bioavailability (rats), 673homogenates, biotransformation of tipredane (mice, rats, humans),

532

inactivation of steroid hydroxylases, cytochrome P-450 (rats), 26-intestine preparation, first-pass metabolism, salicylamide (rats), 556metabolic interaction, morphine and naloxone (humans), 218nondeficient sparteine/debrisoquine monooxygenase, variant allo-

zymes (humans), 334

perfused, pharmacokinetics, U-74006F (rats), 373rifampicin-inducible cytochrome P.450, product, P45OIIIA gene

subfamily (humans), 197selective inactivation of cytochrome P-450, phencyclidine (rabbits), 7

slices, foreign compound-metabolizing activity, compared to hepato-

cytes (humans, dogs, rats), 526spironolactone metabolism (guinea pigs), 186

stereoselective oxidation of nilvadipine (rats, dogs), 64Liver microsomes

bambuterol metabolism (rats), 3 1 1epoxide formation, deimidazolation, antimycotic croconazole (rab-

bits),564

formation of inhibitory complex, isosafrole metabolite, cytochrome P-

450 PB-B (rats), 449hydroxylation of4,4’-methylenebis(2-chloroaniline)(dogs, guinea pigs,

rats), 406

metabolism of acrylonitrile, 2-cyanoethylene oxide (rats), 481

monooxygenase-mediated covalent binding, methoxychlor (humans,

rats), 487

oxidation, sensitivity of pyrazole to antibody, cytochrome P.450 iso-zyme (rabbits), 694

oxidative biotransformation, warfarin hydroxylation (humans), 265Lovastatin, physiological disposition (dogs), 166

Lungimmunohistochemical study of cytochrome P.450, monoclonal anti-

bodies(mice), 551metabolism of acrylonitrile, 2-cyanoethylene oxide (rats). 481toxicity oftrichloroethylene (mice), 106

LY2O1 1 16, metabolism and disposition, pharmacokinetics (rats), 656

fl-Lyase, quantitation of multiple pathways of metabolism, nephrotoxic

cysteine conjugates, 297

Macrophages. uptake of clodronate (mice), 690

Methoxychlor, monooxygenase-mediated covalent binding, liver micro-somes (rats, humans), 487

Methoxyflurane, enhancement ofallyl alcohol hepatotoxicity (rats), 1 17

a-Methylbenzylaminobenzotriazole, inhibition of 3-methylindole bioac-

tivation (goats), 37

4,4’-Methylenebis(2-chloroaniline), hydroxylation by liver microsomes

(dogs, guinea pigs, rats), 4063-Methylindole, inhibition of bioactivation, cytochrome P-450 suicide

substrates (goats), 37Methylphenobarbital, racemic, stereoselective metabolism, pharmacoki-

netics (humans), 212Metoprolol, atenolol and, central nervous system kinetics (dogs), 82Monoclonal antibodies

immunohistochemical study ofcytochrome P-450, lung (mice), 551isozyme-specific. induction ofhepatic cytochrome P.450, clotrimazole

(rats),360

Monooxygenase

activities of drug oxidases, cultured hepatocytes (rats), 20

flavin-containing, N-oxidation, senecionine (rats), 380hepatic activity, influence ofphenobarbital, gestation stages (rats), 579-mediated covalent binding of methoxychlor, liver microsomes (hu-

mans, rats), 487

Morphine

(8S-(glutathion-S-yl)dihydromorphinone, novel rnetabolite, bile

(guinea pigs), 77naloxone and, metabolic interaction, liver (humans), 218

Muscle, metabolism pf atrial natriuretic peptide (rats), 14Mutagenesis, 2,6-diaminotoluene metabolism and disposition (rats), 612

Naloxone, morphine and, metabolic interaction, liver (humans), 218Naltrexone, disposition and pharmacokinetics (monkeys), 583

l-Naphthol, systemic intestinal metabolism (rats), 573

Naproxen, 6-desmethylnaproxen sulfate as metabolite, human plasma,

43

Nephrectomy, pharmacokinetics, recombinant tumor necrosis factor-a(rats), 369

Nephrotoxicity, acetaminophen, susceptibility, middle-aged rats, 139Nilvadipine. stereoselective oxidation (rats, dogs), 64Nitrogen, -containing steroid, hepatocyte metabolism (rats), 606

Omeprazole, identification of main urinary metabolites (humans), 69

Paraquat, N-methylation as toxication route (guinea pigs), 180D-Pencillamine, pharmacokinetics of albumin conjugates (rats), 208

Pentobarbital, influence of nutritional status, pharmacokinetics, phar-macodynamics (rats), 365

Perfusion, organ, effect, renal drug transport (rats), 32

Phencyclidinefactors affecting biotransformation, human liver and placenta, 271

selective inactivation ofcytochrome P.450 (rabbits), 7

716 SUBJECT INDEX

Xenobiotics, N-methylation as toxication route (guines pigs), 180

Phenobarbital

dose-related effects, hepatic glutathione-S-transferase activity, ligandinlevels (rats), 677

influence on hepatic monooxygenase activity, gestation stages (rats),

579

Phenol, stimulation of bioactivation of hydroquinone, 348Phenol sulfotransferase, human intestinal, assay conditions, thermolabile

form, 255Placenta, factors affecting phencyclidine biotransformation (humans),

271

Plasma

bovine and porcine, metabolic degradation, Leu27-bGRF(l-29)NH3,393

6-desmethylnaproxen sulfate, metabolite of naproxen, 43Pregnancy

disposition ofaromatic retinoids (rats), 646, 652pharmacokinetics of salicylate (rats), 87

Progesterone, 17�9-estradiol and, nasal absorption and metabolism (rats),

248

2-Propentanal acetals, metabolic conversion to valproic acid, 513Propranolol, 4’-�ethylthio derivative, pharmacokinetics and metabo-

lism (dogs), 4952-n-Propyl-4-pentenoio acid, covalent binding to protein, valproic acid,

hepatocytes (rats), 123

Proteinbinding ofdiflunisal, species differences, 221covalent binding of valproic acid, hepatotoxic metabolite, hepatocytes

(rats), 123influence of nutritional status, pharmacokinetics and pharmacody-

namics, pentobarbital (rats), 365

Psoriasis, biotransformation of etretinate (mice), 618Pyrazole, oxidation, anti-3a IgG inhibition, liver microsomes (rabbits),

694

Renin, inhibitor peptide, U-7 1038 disposition and metabolism (rats),

518

Retinoids

aromaticbiotransformation, etretinate and etretin (mice), 618disposition, influence of pregnancy (rats), 646, 652

Rifampicin, -inducible liver cytochrome P.450, product, P45OIIIA gene

subfamily (humans), 197

Salicylamide, first-pass metabolism (rats), 556Salicylate, pharmacokinetics, pregnancy (rats), 87Sandostatin, disposition (rats), 699

Senecionine

bioactivation and detoxication, cytochrome P-450 enzymes, liver(rats), 387

N-oxidation, flavin-containing monooxygenase (rats), 380

Sertraline, metabolism and disposition (rats, dogs), 542Sertraline carbamoyl-O-glucuronide, characterization (dogs), 58

Sexhepatic drug metabolism as function ofage (rats), 1 14organs, metabolism, atrial natriuretic peptide (rats), 14

SK&F 86002, pharmacokinetics and metabolism (rats), 174

Skin, biotransformation ofetretinate (mice), 618

Somatostatin analogue, sandostatin disposition (rats), 699Sparteine, debrisoquine monooxygenase, variant allozymes (humans),

334Species differences, protein binding of diflunisal, 221

Spironolactone

adrenal activation, regional differences (guinea pigs), 709metabolism in target tissues (guinea pigs), 186

Steroids

adrenal activation ofspironolactone, regional differences (guinea pigs),

biotr��formation of tipredane, liver homogenates (mice, rats, hu-

mans), 532inactivation ofliver steroid hydroxylases, cytochrome P.450 (rats), 26

nitrogen-containing, hepatocyte metabolism (rats), 606Sulfadimidine, pharmacokinetics, tick-borne fever, trypanosomiasis

(goats), 1

Tegison, see Etretinate

Tenoxicam, oxidation by leukocyte peroxidases, hydrogen peroxide, 463

Terbutaline, bambuterol metabolism, liver microsomes (rats), 31 1Testes, spironolactone metabolism (guinea pigs), 1863,3’,4,4’-Tetrachlorobiphenyl, hydroxylated metabolites, excretion and

tissue retention (mice), 441Thalidomide, plasma pharmacokinetics, urinary excretion, healthy male

volunteers, 402

l-[l-(2-Thienyl)cyclohexyl]piperidine, pharmacokinetics (rats), 641Tick-borne fever, effect on sulfadimidine pharmacokinetics (goats), 1Tipredane, biotransformation in liver homogenates (mice, rats, humans),

532

Trichloroethylene, pulmonary toxicity (mice), 106Trichothecenes, enterohepatic circulation, T-2 toxin metabolites (rats),

600Trimebutine, metabolic pathways, deuterium-labeled metabolite (rats),

455

Trypanosoma brucei, effect on sulfadimidine pharmacokinetics (goats),

T-2 toxin, enterohepatic circulation of metabolites (rats), 600Tumor necrosis factor-a, recombinant, pharmacokinetics (rats), 369

U-71038, disposition and metabolism, novel renin inhibitor peptide

(rats), 518U-74006F, pharmacokinetics, perfused liver (rats), 373Urethane, inhibition of metabolism, dimethyl sulfoxide (mice), 469

Valproic acid

covalent binding to protein, hepatotoxic metabolite, hepatocytes (rats),123

metabolic conversion of 2-propylpentanal, 513

Warfarin, hydroxylation, oxidative biotransformation, human liver mi-

crosomes, 265WR-1065, disposition ofethiofos (monkeys), 304